CLRB Cellectar Biosciences Inc

Price (delayed)

$2.09

Market cap

$19.75M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.84

Enterprise value

-$12.71M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 7

Cellectar Biosciences is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of proprietary drugs for the treatment of cancer, independently and through research and development collaborations. ...

Highlights
The company's EPS has surged by 80% YoY and by 42% QoQ
Cellectar Biosciences's net income has increased by 23% YoY but it has decreased by 7% QoQ

Key stats

What are the main financial stats of CLRB

CLRB stock price

How has the Cellectar Biosciences stock price performed over time
Intraday
-6.28%
1 week
-11.06%
1 month
-19.31%
1 year
-59.81%
YTD
-29.15%
QTD
-24.82%

Financial performance

How have Cellectar Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$23.53M
Net income
-$22.32M
Gross margin
N/A
Net margin
N/A
Cellectar Biosciences's operating income has increased by 39% YoY but it has decreased by 5% from the previous quarter
Cellectar Biosciences's net income has increased by 23% YoY but it has decreased by 7% QoQ

Price vs fundamentals

How does CLRB's price correlate with its fundamentals

Growth

What is Cellectar Biosciences's growth rate over time

Valuation

What is Cellectar Biosciences stock price valuation
P/E
N/A
P/B
0.56
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 80% YoY and by 42% QoQ
The price to book (P/B) is 78% lower than the 5-year quarterly average of 2.7 and 68% lower than the last 4 quarters average of 1.9

Efficiency

How efficient is Cellectar Biosciences business performance
The company's return on equity rose by 44% QoQ and by 32% YoY
The company's return on assets rose by 25% QoQ and by 8% YoY

Dividends

What is CLRB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLRB.

Financial health

How did Cellectar Biosciences financials performed over time
The total assets has soared by 168% YoY
The total liabilities has grown by 9% YoY and by 6% from the previous quarter
The company's debt is 95% lower than its equity
The company's debt to equity has shrunk by 89% QoQ and by 29% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.